Management of patients with arterial hypertension and heart rate over 80 bpm: resolution of the expert council

Сlinical and population studies have shown that elevated heart rate (HR) in patients with arterial hypertension significantly increases the risk of organ damage, development of cardiovascular events and overall mortality. Therefore, measurement of resting HR should be a component of standard hypertensive patients examination. This simple parameter was shown to reliably reflect sympathetic nervous system activity. A cutoff point for resting HR over 80 beats per minute (bpm) has been proposed to be a marker of sympathetic overdrive and an independent cardiovascular risk factor. However, the rationale and target for HR reduction in hypertension without cardiovascular diseases are still controversial. It is necessary to take into account the tolerance of tachycardia, blood pressure level, the HR level and comorbidity before starting HR reduction therapy. Increased resting HR may be a clinical sign of sympathetic overdrive, but also a symptom of anemia, thyrotoxicosis, hypovolemia, chronic heart failure, and other conditions. It is also necessary to consider patient’s metabolic status and lifestyle. Thе review summarizes expert council opinion on the management of patients with hypertension and HR over 80 bpm, including the issue of beta-blocker indications.

1. NCD Risk Factor Collaboration (NCD-RisC). World-wide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. https://doi.org/10.1016/S0140-6736(21)01330-1

2. Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3785

3. Balanova YuA, Shalnova SA, Kutsenko VA, Imaeva AE, Kapustina AV, Muromtseva GA, et al. Contribution of hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003. (In Russ.) https://doi.org/10.15829/1728-8800-2021-3003

4. Shalnova SA, KonradiAO, Balanova YuA, DeevAD, ImaevaAE, Muromtseva GA, et al. What factors do influence arterial hypertension control in Russia. Cardiovascular Therapy and Prevention. 2018;17(4):53–60. (In Russ.) https://doi.org/10.15829/1728-8800-2018-4-53-60

5. Shalnova SA, Deev AD, Belova OA, Grinshtein YuI, Duplyakov DV, Efanov AYu, et al. Heart rate and its association with the main risk factors in the population of men and women of working age. Rational Pharmacotherapy in Cardiology. 2017;13(6):819– 826. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-819-826

6. Shabalin VV, Grinshtein YI, Ruf RR, Shtrikh AYu. Interrelations between heart rate, hypertension, and the other cardio-vascular risk factors in Krasnoyarsk Krai population. The Siberian Medical Journal. 2019;34(3):179–185. (In Russ.) https://doi.org/10.29001/2073-8552-2019-34-3-179-185

7. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011;58(5):745–750. https://doi.org/10.1161/HYPERTENSIONAHA.111.173104

8. Shen L, Wang Y, Jiang X, Ren Y, Han Ch, Yang Y. Dose-response association of resting heart rate and hypertension in adults: a systematic review and meta-analysis of cohort studies. Medicine. 2020;99(10):e19401. https://doi.org/10.1097/MD.0000000000019401

9. Aune D, Sen A, ó’Hartaigh B, Janszky I, Romundstad PR, Tonstad S, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality — A systematic review and dose-response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27(6):504–517. https://doi.org/10.1016/j.numecd.2017.04.004

10. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109(5):685–692. https://doi.org/10.1016/j.amjcard.2011.10.025

11. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162(20):2313–2321. https://doi.org/10.1001/archinte.162.20.2313

12. Ho JE, Bittner V, DeMicco DA, Breazna A, Deedwania PC, Waters DD. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010;105(7):905–911. https://doi.org/10.1016/j.amjcard.2009.11.035

13. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327–1334. https://doi.org/10.1093/eurheartj/ehn123

14. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010;31(18):2271–2279. https://doi.org/10.1093/eurheartj/ehq225

15. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Devereux RB. Effect of changing heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol. 2012;109(5):699– 704. https://doi.org/10.1016/j.amjcard.2011.10.026

16. Sobieraj P, Siński M, Lewandowski J. Resting heart rate and cardiovascular outcomes during intensive and standard blood pressure reduction: an analysis from SPRINT Trial. Journal of Clinical Medicine. 2021;10(15):3264. https://doi.org/10.3390/jcm10153264

17. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. https://doi.org/10.1056/NEJMoa1511939

18. Lonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/ TRANSCEND. Clin Res Cardiol. 2014;103(2):149–159. https://doi.org/10.1007/s00392-013-0644-4

19. Gillman MW, Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125(4):1148–1154. https://doi.org/10.1016/0002-8703(93)90128-v

20. Gaye B, Valentin E, Xanthakis V Perier MC, Celermajer DS, Shipley M. Association between change in heart rate over years and life span in the Paris Prospective 1, the Whitehall 1, and Framingham studies. Sci Rep. 2024;14:20052. https://doi.org/10.1038/s41598-024-70806-8

21. Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension. 2001;37(5):1256– 1261. https://doi.org/10.1161/01.hyp.37.5.1256

22. Sun N, Chen Y, Xi Y, Wang H, Wang L. Аssociation between heart rate and major adverse cardiovascular events among 9,991 hypertensive patients: a multicenter retrospective follow-up study. Front Cardiovasc Med. 2021;8:741784. https://doi.org/10.3389/fcvm.2021.741784

23. Zhong C, Zhong X, Xu T, Peng H, Li H, Zhang M. Combined effects of hypertension and heart rate on the risk of stroke and coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China. Hypertens Res. 2015;38:883– 888. https://doi.org/10.1038/hr.2015.90

24. Grassi G, Drager LF. Sympathetic overactivity, hypertension and cardiovascular disease: state of the art. Curr Med Res Opin. 2024;40(sup1):5–13. https://doi.org/10.1080/03007995.2024.2305248

25. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–1536. https://doi.org/10.1093/eurheartj/ehm236

26. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. https://doi.org/10.1097/HJH.0000000000003480

27. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, et al. 2024 Clinical practice guide-lines for hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6117

28. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb DC, et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guide-lines. Hypertension. 2018;71(6): e13-e115. https://doi.org/10.1161/HYP.0000000000000065

29. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026

30. Grigin VA, Danilov NM, Sagaydak OV, Shchelkova GV, Chazova IE. Methods of sympathetic activity evaluation in patients with systemic refractory hypertension. Systemic Hypertension. 2014;11(4):21–26. (In Russ.)

31. Barbarash OL, Karpov YuA, Panov AV, Akchurin RS, Alekyan BG, Alekhin MN, et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6110

32. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415–3537. https://doi.org/10.1093/eurheartj/ehae177

33. Galyavich AS, Tereshchenko SN, Uskach TM, Ageev FT, Aronov DM, Arutyunov GP, et al. 2024 Clinical practice guide-lines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6162

34. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368

35. Arakelyan MG, Bockeria LA, Vasilieva EYu, Golitsyn SP, Golukhova EZ, Gorev MV, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4594

36. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45(36):3314–3414. https://doi.org/10.1093/eurheartj/ehae176

37. Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, et al. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. J Hypertens. 2016;34(5):813–821. https://doi.org/10.1097/HJH.0000000000000865

38. Lequeux B, Uzan C, Rehman MB. Does resting heart rate measured by the physician reflect the patient’s true resting heart rate? White-coat heart rate. Indian Heart J. 2018;70(1):93–98. https://doi.org/10.1016/j.ihj.2017.07.015

39. Hansen TW, Thijs L, Boggia J, Li Y, Kikuya M, Björklund-Bodegård K, et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension. 2008;52(2):229–235. https://doi.org/10.1161/HYPERTENSIONAHA.108.113191

40. Böhm M, Schwantke I, Mahfoud F, Lauder L, Wagenpfeil S, de la Sierra A, et al. Association of clinic and ambulatory heart rate parameters with mortality in hypertension. J Hypertens. 2020;38(12):2416–2426. https://doi.org/10.1097/HJH.0000000000002565

41. Mayuga KA, Fedorowski A, Ricci F, Gopinathannair R, Dukes JW, Gibbons Ch, et al. Sinus tachycardia: a multidisciplinary expert focused review. Circ Arrhythm Electrophysiol. 2022;15(9): e007960. https://doi.org/10.1161/CIRCEP.121.007960

42. Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol. 2013;61(8):793–801. https://doi.org/10.1016/j.jacc.2012.07.074

43. Ghuran A, van Der Wieken LR, Nolan J. Cardiovascular complications of recreational drugs. Br Med J. 2001;323(7311):464–466. https://doi.org/10.1136/bmj.323.7311.464

44. Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013;8(4):169–176.

45. Henning A, Krawiec C. Sinus Tachycardia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Accessed Feb 19, 2025. URL: https://www.ncbi.nlm.nih.gov/books/NBK553128/

46. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020;142(15):e214–e233. https://doi.org/10.1161/CIR.0000000000000905

47. Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JMC, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2009;55(2):567–574. https://doi.org/10.1161/HYPERTENSIONAHA.109.144808

48. Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54(13):1154–1161. https://doi.org/10.1016/j.jacc.2009.04.087

49. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225. https://doi.org/10.1161/CIRCULATIONAHA.105.595496

50. Brunner S, Krewitz C, Winter R, von Falkenhausen A, Kern A, Brunner D, et al. Acute alcohol consumption and arrhythmias in young adults: the MunichBREW II study. Eur Heart J. 2024;45(46):4938–4949. https://doi.org/10.1093/eurheartj/ehae695

51. Manta E, Konstantinidis D, Dimitriadis K, Tatakis F, Drogkaris S, Polyzos D. Correlations between sympathetic nervous system activity and smoking, as well as unattended blood pressure in essential hypertension. Eur Heart J. 2021;42(Supp.1): ehab724.2599. https://doi.org/10.1093/eurheartj/ehab724.2599

52. Hegde SM, Solomon SD. Influence of physical activity on hypertension and cardiac structure and function. Curr Hypertens Rep. 2015;17(10):77. https://doi.org/10.1007/s11906-015-0588-3

53. Pinckard K, Baskin KK, Stanford KI. Effects of exercise to improve cardiovascular health. Front Cardiovasc Med. 2019;6:69. https://doi.org/10.3389/fcvm.2019.00069

54. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482–1489. https://doi.org/10.1016/j.jacc.2008.06.048

55. Orlova YaA, Mikhailov GV, Khezheva FM, Vitsenya MV, Ageyev FT, et al. Effect of bisoprolol therapy on parameters of peripheral and central blood pressure, arterial stiffness, left ventricular diastolic function and quality of life in patients with arterial hypertension (KLUCH study). Heart: Journal for Practitioners. 2012;11(6):342–350. (In Russ.)

56. Feng Z, Zhang L, Wang Y, Guo H, Liu J. Efficacy and safety of bisoprolol in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:3067–3083. https://doi.org/10.2147/COPD.S438930

57. Giesecke HG, Buchner-Möll D. Three years of experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1990;16(Suppl. 5):S175-S178.

58. Fogari P, Zoppi A, Tettamanti F, Poletti L, Lazzari P, Pasotti C, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and of the lipid status before treatment. J Cardiovasc Pharmacol. 1990;16(Suppl. 5): 76–80.

59. Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11:14. https://doi.org/10.1186/1475-2840-11-14

60. Ray S, Nair T, Sawhney J, Erwinanto, Rosman A, Reyes E, et al. Role of β-blockers in the cardiovascular disease continuum: a collaborative Delphi survey-based consensus from Asia-Pacific. Curr Med Res Opin. 2023;39(12):1671–1683. https://doi.org/10.1080/03007995.2023.2256218

61. Bokeria LA, Glukhova EZ, Popov SV, Artyukhina EA, Bazaev VA, Batalov RE, et al. Supraventricular tachycardia. Clinical guidelines. 2020 (In Russ.) [сited 2025 March 19]. Available from: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_NT.pdf

62. Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, et al. Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J. 2018;39(33):3128–3134. https://doi.org/10.1093/eurheartj/ehy451

63. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11): e113048. https://doi.org/10.1371/journal.pone.0113048

64. Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. Br Med J. 2024;385:e079108. https://doi.org/10.1136/bmj-2023-079108

65. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068. https://doi.org/10.1016/S0140-6736(15)00257-3

66. Nedoshivin AO, Orlova OV. Use of beta-blockers at different stages of cardiovascular continuum. Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(4):249–253. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-4-249-253

67. Aksenova AV, Sivakova OA, Blinova NV, Danilov NM, Elfimova EM, Kislyak OA, et al. Expert consensus of the Russian Medical Society on Arterial Hypertension on diagnosis and treatment of resistant arterial hypertension. TTer Arkh. 2021;93(9):1018–1029. (In Russ.) https://doi.org/10.26442/00403660.2021.09.201007

68. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan D, MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45:3912– 4018. https://doi.org/10.1093/eurheartj/ehae178

69. Palatini P, Winnicki M, Santonastaso M, Venuto G De, Zanata G, Bertolo O, et al. Reproducibility of heart rate measured in the clinic and with 24-hour intermittent recorders. Am J Hypertens. 2000;13:92–98. https://doi.org/10.1016/s0895-7061(99)00170-3